

PHARMACY COVERAGE GUIDELINE

QINLOCK™ (riporetinib) oral Generic Equivalent (if available)

This Pharmacy Coverage Guideline (PCG):

- Provides information about the reasons, basis, and information sources we use for coverage decisions
- Is not an opinion that a drug (collectively “Service”) is clinically appropriate or inappropriate for a patient
- Is not a substitute for a provider’s judgment (Provider and patient are responsible for all decisions about appropriateness of care)
- Is subject to all provisions e.g. (benefit coverage, limits, and exclusions) in the member’s benefit plan; and
- Is subject to change as new information becomes available.

Scope

- This PCG applies to Commercial and/or Marketplace plans
- This PCG does not apply to the Federal Employee Program, Medicare Advantage, Medicaid or members of out-of-state Blue Cross and/or Blue Shield Plans

Instructions & Guidance

- To determine whether a member is eligible for the Service, read the entire PCG.
- This PCG is used for FDA approved indications including, but not limited to, a diagnosis and/or treatment with dosing, frequency, and duration.
- Use of a drug outside the FDA approved guidelines, refer to the appropriate Off-Label Use policy.
- The “Criteria” section outlines the factors and information we use to decide if the Service is medically necessary as defined in the Member’s benefit plan.
- The “Description” section describes the Service.
- The “Definition” section defines certain words, terms or items within the policy and may include tables and charts.
- The “Resources” section lists the information and materials we considered in developing this PCG
- **We do not accept patient use of samples as evidence of an initial course of treatment, justification for continuation of therapy, or evidence of adequate trial and failure.**
- Information about medications that require prior authorization is available at www.azblue.com/pharmacy. You must fully complete the [request form](#) and provide chart notes, lab workup and any other supporting documentation. The prescribing provider must sign the form. Fax the form to BCBSAZ Pharmacy Management at (602) 864-3126 or email it to Pharmacyprecert@azblue.com.

Medical Necessity Requirements for QINLOCK (riporetinib)

Criteria for Initial Therapy:

Prescriber Qualifications

- Prescribed by an Oncologist or in consultation with an Oncologist

Indication

- Advanced gastrointestinal stromal tumor (GIST) with prior treatment using 3 or more kinase inhibitors including imatinib
- Other oncologic direct treatment uses listed in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1 and 2A

ORIGINAL EFFECTIVE DATE: 08/20/2020 | ARCHIVE DATE: | LAST REVIEW DATE: 08/21/2025 | LAST CRITERIA REVISION DATE: 08/15/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

QINLOCK™ (riporetinib) oral Generic Equivalent (if available)

Age Requirement

- 18 years or older

Baseline Clinical Evaluation

- Blood pressure is adequately controlled
- Ejection fraction is greater than 50 percent evaluated by echocardiogram or MUGA
- Negative pregnancy test (if applicable)
- Eastern Cooperative Oncology Group (ECOG) Performance Status is 0 to 2

Brand Specific Criteria

- Have failure, contraindication or intolerance with **THREE** generic equivalents (when available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the United States Food and Drug Administration (FDA) (see Definitions section)

Safety

- No severe renal impairment (creatinine clearance 15 to 29 mL/min)
- No concomitant drug use with strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, etc.)

Documentation Requirements

- A completed request form must be submitted, including:
 - Chart notes
 - Lab results (blood pressure, ejection fraction, pregnancy test, ECOG status)
 - Supporting clinical documentation

Initial Therapy Criteria Approval Duration:

- 6 months OR end of plan year
-

Criteria for Continuation of Therapy (renewal therapy)

Note: Manufacturer assistance (e.g., coupons, samples, etc.) are not considered for continuation of therapy

Prescriber Qualifications

- Continues to be seen by an Oncologist or in consultation with an Oncologist

Clinical Response

- No evidence of disease progression or unacceptable toxicity

Adherence

- Adherence to the prescribed therapy regimen has been documented
- Dose is at least 100 mg once daily

PHARMACY COVERAGE GUIDELINE

QINLOCK™ (riporetinib) oral Generic Equivalent (if available)

Brand Specific Criteria

- Have failure, contraindication or intolerance with **THREE** generic equivalents (when available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

Safety

- No significant adverse drug effects such as:
 - Life threatening hypertension not controlled by antihypertensive medications
 - Severe or life threatening left ventricular systolic dysfunction
 - Severe or life threatening adverse reactions that recur after dose adjustment
- No severe renal impairment (creatinine clearance 15 to 29 mL/min)
- No concomitant drug use with strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin)

Documentation Requirements

- Chart notes
- Supporting clinical documentation with evidence of improvement in given indication
- Lab values that confirm safe use from above criteria

Continuation Therapy Criteria Approval Duration:

- 12 months OR end of plan year
-

Criteria for Off-Label Use Requests:

Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. Off-Label Use of Non-Cancer Medications
 2. Off-Label Use of Cancer Medications
-

Description:

Qinlock (riporetinib) is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Definitions:

U.S. Food and Drug Administration (FDA) MedWatch Forms for FDA Safety Reporting
[MedWatch Forms for FDA Safety Reporting | FDA](#)

PHARMACY COVERAGE GUIDELINE

**QINLOCK™ (riporetinib) oral
Generic Equivalent (if available)**

Activities of daily living (ADL):

Instrumental ADL:

Prepare meals, shop for groceries or clothes, use the telephone, manage money, etc.

Self-care ADL:

Bathe, dress and undress, feed self, use the toilet, take medications, not bedridden

Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0:

Grade 1	Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated
Grade 2	Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL*
Grade 3	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL**
Grade 4	Life-threatening consequences; urgent intervention indicated
Grade 5	Death related to AE
U.S. Department of Health and Human Services, National Institutes of Health, and National Cancer Institute	

ECOG Performance status:

Eastern Co-operative Oncology Group (ECOG) Performance Status	
Grade	ECOG description
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work
2	Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours
3	Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4	Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
5	Dead
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982	

NCCN recommendation definitions:

Category 1:

Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A:

Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B:

Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3:

Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate

Resources:

Qinlock (riporetinib) product information, revised by Deciphera Pharmaceuticals, LLC 10-2023. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed May 10, 2025.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Gastrointestinal Stromal Tumors (GISTs) Version 1.2025. Updated April 17, 2025. Available at <https://www.nccn.org>. Accessed May 10, 2025.

ORIGINAL EFFECTIVE DATE: 08/20/2020 | ARCHIVE DATE: | LAST REVIEW DATE: 08/21/2025 | LAST CRITERIA REVISION DATE: 08/15/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINE

QINLOCK™ (ripretinib) oral Generic Equivalent (if available)

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.

ORIGINAL EFFECTIVE DATE: 08/20/2020 | ARCHIVE DATE: | LAST REVIEW DATE: 08/21/2025 | LAST CRITERIA REVISION DATE: 08/15/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.